CAF-immune cell crosstalk and its impact in immunotherapy
Seminars in Immunopathology · 2023-03 · 45 (2) · 203-214
DOI: 10.1007/s00281-022-00977-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Immunopathology, online erschienen am 08.12.2022. Verfasst von Ana Maia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. ana.maia@uni-tuebingen.de. Hauptthemen laut MEDLINE: Neoplasms, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German Excellence Strategy, Universitätsklinikum Tübingen.
Abstract (Originalsprache)
Tumour cells do not exist as isolated entities. Instead, they are surrounded by a variety of cells and extracellular matrix, which form the tumour microenvironment (TME). The interaction between cancer cells and their microenvironment is increasingly acknowledged as essential in dictating the outcome of the patients. The TME includes everything that surrounds tumour cells and is often highjacked by the latter to promote their growth, invasion, and immune escape. Immune cells and cancer-associated fibroblasts (CAFs) are essential components of the TME, and there is increasing evidence that their interaction constitutes a major player not only for tumour progression but also for therapy response. Recent work in the field of immuno-oncology resulted in the development of novel therapies that aim at activating immune cells against cancer cells to eliminate them. Despite their unprecedented success, the lack of response from a large portion of patients highlights the need for further progress and improvement. To achieve its ultimate goal, the interaction between cancer cells and the TME needs to be studied in-depth to allow the targeting of mechanisms that are involved in resistance or refractoriness to therapy. Moreover, predictive and prognostic biomarkers for patient stratification are still missing. In this review, we focus on and highlight the complexity of CAFs within the TME and how their interaction, particularly with immune cells, can contribute to treatment failure. We further discuss how this crosstalk can be further dissected and which strategies are currently used to target them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. ana.maia@uni-tuebingen.de.
- Cluster of Excellence iFIT (EXC2180), Image-Guided and Functionally Instructed Tumor Therapies, University of Tübingen, Tübingen, Germany. ana.maia@uni-tuebingen.de.
- Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
- Cluster of Excellence iFIT (EXC2180), Image-Guided and Functionally Instructed Tumor Therapies, University of Tübingen, Tübingen, Germany.
- SFB1399 Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer, University of Cologne, Koln, Germany.
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), University of Tübingen, Tübingen, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
- German Excellence Strategy
- Universitätsklinikum Tübingen
Zitieren
APA
Maia, A., Schöllhorn, A., Schuhmacher, J., & Gouttefangeas, C. (2023). CAF-immune cell crosstalk and its impact in immunotherapy. Seminars in Immunopathology, 45(2), 203-214. https://doi.org/10.1007/s00281-022-00977-x
Vancouver
Maia A, Schöllhorn A, Schuhmacher J, Gouttefangeas C. CAF-immune cell crosstalk and its impact in immunotherapy. Seminars in Immunopathology. 2023;45(2):203-214. doi:10.1007/s00281-022-00977-x
BibTeX
@article{Maia2023,
author = {Maia, Ana and Schöllhorn, Anna and Schuhmacher, Juliane and Gouttefangeas, Cécile},
title = {CAF-immune cell crosstalk and its impact in immunotherapy},
journal = {Seminars in Immunopathology},
year = {2023},
volume = {45},
number = {2},
pages = {203--214},
doi = {10.1007/s00281-022-00977-x}
}
EUVIMED